Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

PEPG

PepGen Inc

Last Close
May 16 • 04:00PM ET
13.65
Dollar change
-0.17
Percentage change
-1.23 		%
Held by: VTI VXF IWM IWN VTWO IWO IWC AVSC IWV RYLD
IndexRUT P/E- EPS (ttm)-3.25 Insider Own16.15% Shs Outstand32.42M Perf Week2.32%
Market Cap442.53M Forward P/E- EPS next Y-2.66 Insider Trans95.56% Shs Float27.18M Perf Month18.70%
Income-80.33M PEG- EPS next Q-0.74 Inst Own70.05% Short Float1.66% Perf Quarter-3.26%
Sales0.00M P/S- EPS this Y12.47% Inst Trans-0.43% Short Ratio5.37 Perf Half Y217.44%
Book/sh5.53 P/B2.47 EPS next Y8.03% ROA-39.37% Short Interest0.45M Perf Year-5.93%
Cash/sh5.40 P/C2.53 EPS next 5Y- ROE-46.72% 52W Range3.72 - 17.51 Perf YTD100.74%
Dividend Est.- P/FCF- EPS past 5Y-172.30% ROI-41.04% 52W High-22.04% Beta1.65
Dividend TTM- Quick Ratio15.78 Sales past 5Y0.00% Gross Margin- 52W Low266.94% ATR (14)1.07
Dividend Ex-Date- Current Ratio15.78 EPS Y/Y TTM2.65% Oper. Margin0.00% RSI (14)53.42 Volatility7.65% 8.55%
Employees64 Debt/Eq0.11 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price21.60
Option/ShortNo / Yes LT Debt/Eq0.09 EPS Q/Q8.44% Payout- Rel Volume0.26 Prev Close13.82
Sales Surprise- EPS Surprise18.85% Sales Q/Q- EarningsMay 14 AMC Avg Volume84.03K Price13.65
SMA205.99% SMA503.37% SMA20057.54% Trades Volume21,483 Change-1.23%
Date Action Analyst Rating Change Price Target Change
Dec-21-22Initiated H.C. Wainwright Buy $26
May-15-24 01:20PM
PepGen Q1 Loss Narrows
(MT Newswires)
May-14-24 10:55PM
PEPG Stock Earnings: PepGen Beats EPS for Q1 2024
(InvestorPlace) +5.19%
04:02PM
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Apr-12-24 01:30PM
Hedge Fund and Insider Trading News: ExodusPoint Capital Management, Bridgewater Associates, Glenview Capital Management, PepGen Inc. (PEPG), HCI Group Inc (HCI), and More
(Insider Monkey)
Mar-13-24 04:05PM
PepGen to Participate in Upcoming Investor Conferences
(GlobeNewswire)
07:00AM Loading…
07:00AM
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
(GlobeNewswire)
Mar-12-24 09:55AM
Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect?
(Zacks)
Mar-11-24 12:00PM
PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock?
(Zacks)
Mar-06-24 11:54PM
PEPG Stock Earnings: PepGen Beats EPS for Q4 2023
(InvestorPlace) -7.34%
04:01PM
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Mar-04-24 07:00AM
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
(GlobeNewswire)
Feb-29-24 03:02AM
14 Stocks With Heavy Insider Buying In 2024
(Insider Monkey) +14.68%
Feb-20-24 08:00AM
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
(GlobeNewswire)
Feb-07-24 07:30AM
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
(GlobeNewswire) +17.63%
Jan-17-24 07:00AM
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
(GlobeNewswire)
07:00AM Loading…
Jan-08-24 07:00AM
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
(GlobeNewswire)
Dec-18-23 08:00AM
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
(GlobeNewswire) +6.03%
Nov-15-23 08:00AM
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
(GlobeNewswire)
Nov-08-23 08:00AM
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
(GlobeNewswire) -10.40%
Oct-12-23 07:00AM
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
(GlobeNewswire) +7.22%
Sep-27-23 04:16PM
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
(GlobeNewswire)
Sep-06-23 04:05PM
PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1
(GlobeNewswire)
08:00AM
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Companys Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences
(GlobeNewswire)
Sep-01-23 08:00AM
PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference
(GlobeNewswire)
Aug-08-23 08:15AM
PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Jun-13-23 04:05PM
PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1
(GlobeNewswire) +10.87%
May-31-23 11:44AM
PepGen (PEPG) Down on Clinical Hold for DM1 Candidate
(Zacks) -5.07%
May-30-23 04:05PM
PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
(GlobeNewswire)
May-18-23 07:00AM
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy
(GlobeNewswire)
May-11-23 07:00AM
PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments
(GlobeNewswire)
08:00AM Loading…
May-04-23 08:00AM
PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference
(GlobeNewswire)
Apr-17-23 08:00AM
PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting
(GlobeNewswire) +23.09%
Apr-13-23 04:05PM
PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference
(GlobeNewswire) +6.07%
Mar-27-23 02:25AM
PepGen Inc. (NASDAQ:PEPG) Q4 2022 Earnings Call Transcript
(Insider Monkey) -16.15%
Mar-23-23 04:05PM
PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Mar-22-23 08:00AM
PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference
(GlobeNewswire)
Mar-21-23 04:05PM
PepGen to Participate in the Stifel 2023 CNS Days Conference
(GlobeNewswire)
Mar-16-23 08:00AM
PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call
(GlobeNewswire) +6.99%
Mar-13-23 08:00AM
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference
(GlobeNewswire)
Feb-27-23 08:50AM
PepGen, Inc. (PEPG) Is a Great Choice for 'Trend' Investors, Here's Why
(Zacks) -6.02%
Feb-09-23 08:00AM
PepGen to Participate in the SVB Securities Global Biopharma Conference
(GlobeNewswire) -5.07%
Jan-31-23 08:50AM
Here's Why Momentum in PepGen, Inc. (PEPG) Should Keep going
(Zacks)
Jan-16-23 05:10AM
Companies Like PepGen (NASDAQ:PEPG) Are In A Position To Invest In Growth
(Simply Wall St.)
Jan-13-23 08:50AM
Here's What Could Help PepGen, Inc. (PEPG) Maintain Its Recent Price Strength
(Zacks)
Dec-21-22 02:25PM
Why This PepGen Analyst Is Bullish On The Biotech Stock
(Benzinga)
Dec-07-22 08:00AM
PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies
(GlobeNewswire)
Dec-01-22 09:55AM
Wall Street Analysts See a 50% Upside in PepGen, Inc. (PEPG): Can the Stock Really Move This High?
(Zacks) -6.42%
Nov-21-22 08:50AM
What Makes PepGen, Inc. (PEPG) a Good Fit for 'Trend Investing'
(Zacks) +5.54%
Nov-15-22 09:55AM
Wall Street Analysts Predict a 68% Upside in PepGen, Inc. (PEPG): Here's What You Should Know
(Zacks)
Nov-14-22 08:00AM
PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates
(GlobeNewswire) +8.33%
Nov-10-22 08:00AM
PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
(GlobeNewswire) +12.92%
Nov-08-22 08:00AM
PepGen to Participate in the Stifel 2022 Healthcare Conference
(GlobeNewswire)
Oct-13-22 01:00PM
PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress
(GlobeNewswire)
Sep-28-22 01:59PM
PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst
(Benzinga) +110.19%
09:25AM
PepGen Touts Encouraging Early-Stage Data From Duchenne Program
(Benzinga)
06:00AM
PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
(GlobeNewswire)
Sep-22-22 08:00AM
PepGen Appoints Habib Dable to Board of Directors
(GlobeNewswire)
Sep-04-22 07:17AM
3 IPO Stocks to Watch in September
(TipRanks)
Aug-12-22 08:00AM
PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
(GlobeNewswire) -6.70%
Aug-08-22 10:51AM
We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth
(Simply Wall St.)
Jul-22-22 07:45AM
PepGen Appoints Caroline Godfrey, Ph.D. to the Companys Scientific Advisory Board
(GlobeNewswire)
Jun-16-22 08:30AM
PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments
(GlobeNewswire) +12.70%
May-27-22 05:22PM
Covetrus and PepGen Stock See Action From Activist Investors
(Barrons.com) +5.63%
May-05-22 11:34PM
PepGen Announces Pricing of Initial Public Offering
(GlobeNewswire)
PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.DirectorFeb 09 '24Buy10.642,557,59327,212,7909,179,273Feb 13 04:33 PM
McArthur James GPresident and CEONov 30 '23Buy4.171,6947,0561,694Dec 05 07:34 AM
McArthur James GPresident and CEOJun 08 '23Option Exercise2.712,3816,4532,381Jun 09 07:06 PM
McArthur James GPresident and CEOJun 08 '23Sale16.042,38138,1880Jun 09 07:06 PM
McArthur James GPresident and CEOJun 07 '23Option Exercise2.718,41922,8158,419Jun 08 05:23 PM
McArthur James GPresident and CEOJun 07 '23Sale16.238,419136,6180Jun 08 05:23 PM
McArthur James GPresident and CEOJun 06 '23Option Exercise2.7118,15049,18618,150Jun 08 05:23 PM
McArthur James GPresident and CEOJun 06 '23Sale16.1818,150293,6600Jun 08 05:23 PM
McArthur James GPresident and CEOJun 05 '23Option Exercise2.715001,355500Jun 06 04:19 PM
McArthur James GPresident and CEOJun 05 '23Sale16.065008,0280Jun 06 04:19 PM
McArthur James GPresident and CEOJun 02 '23Option Exercise2.711,8004,8781,800Jun 06 04:19 PM
McArthur James GPresident and CEOJun 02 '23Sale16.041,80028,8630Jun 06 04:19 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

IMRX

Immuneering Corp

Last Close
May 16 • 04:00PM ET
1.54
Dollar change
-0.03
Percentage change
-1.91 		%
Held by: VTI IWM VXF IWO CNCR VTWO IWC IWN VTWG AVSC
IndexRUT P/E- EPS (ttm)-1.86 Insider Own29.16% Shs Outstand29.27M Perf Week-1.28%
Market Cap45.66M Forward P/E- EPS next Y-1.77 Insider Trans-11.40% Shs Float21.00M Perf Month-17.20%
Income-54.18M PEG- EPS next Q-0.52 Inst Own34.74% Short Float15.28% Perf Quarter-77.01%
Sales0.00M P/S- EPS this Y-3.66% Inst Trans-2.73% Short Ratio4.11 Perf Half Y-70.75%
Book/sh2.65 P/B0.58 EPS next Y8.95% ROA-55.37% Short Interest3.21M Perf Year-81.69%
Cash/sh2.40 P/C0.64 EPS next 5Y- ROE-61.38% 52W Range1.38 - 11.92 Perf YTD-79.05%
Dividend Est.- P/FCF- EPS past 5Y-57.97% ROI-65.42% 52W High-87.08% Beta-0.53
Dividend TTM- Quick Ratio14.38 Sales past 5Y-43.59% Gross Margin-168734.95% 52W Low11.59% ATR (14)0.19
Dividend Ex-Date- Current Ratio14.38 EPS Y/Y TTM4.19% Oper. Margin0.00% RSI (14)36.36 Volatility8.82% 9.91%
Employees68 Debt/Eq0.06 Sales Y/Y TTM-100.00% Profit Margin- Recom1.75 Target Price13.07
Option/ShortNo / Yes LT Debt/Eq0.05 EPS Q/Q5.31% Payout- Rel Volume0.16 Prev Close1.57
Sales Surprise- EPS Surprise2.57% Sales Q/Q- EarningsMay 07 AMC Avg Volume780.63K Price1.54
SMA20-2.41% SMA50-38.60% SMA200-74.40% Trades Volume122,748 Change-1.91%
Date Action Analyst Rating Change Price Target Change
Mar-15-24Reiterated Needham Buy $20 → $15
Mar-15-24Downgrade TD Cowen Outperform → Market Perform
Mar-15-24Downgrade Jefferies Buy → Hold $16 → $3
Dec-01-23Initiated Needham Buy $20
Jun-26-23Resumed Oppenheimer Outperform $25
Apr-19-23Upgrade Morgan Stanley Underweight → Equal-Weight $5 → $14
Apr-19-23Upgrade Mizuho Neutral → Buy $10 → $20
Mar-30-23Initiated Mizuho Neutral $10
Feb-03-23Downgrade Morgan Stanley Equal-Weight → Underweight $12 → $5
Jul-08-22Initiated Chardan Capital Markets Buy $18
Show Previous Ratings
May-07-24 10:55PM
IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024
(InvestorPlace) -5.45%
04:05PM
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
(GlobeNewswire)
May-06-24 04:30PM
Immuneering Recognizes Melanoma Awareness Month
(GlobeNewswire)
Apr-09-24 12:00PM
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
(GlobeNewswire)
Apr-03-24 04:05PM
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
(GlobeNewswire)
08:00AM Loading…
Mar-27-24 08:00AM
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
(GlobeNewswire)
Mar-18-24 11:02AM
Immuneering (IMRX) Plummets 71% in One Week: Here's Why
(Zacks) +34.03%
Mar-14-24 07:00AM
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
(GlobeNewswire) -50.68%
Mar-12-24 08:00AM
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
(GlobeNewswire)
Mar-11-24 08:00AM
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
(GlobeNewswire) -9.53%
Mar-06-24 08:00AM
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
(Newsfile)
Mar-05-24 05:00PM
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
(GlobeNewswire)
Mar-04-24 08:00AM
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
(GlobeNewswire)
Mar-03-24 07:01PM
Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results
(GuruFocus.com)
Mar-01-24 08:00AM
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
(GlobeNewswire)
08:00AM Loading…
Feb-20-24 08:00AM
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
(GlobeNewswire)
Feb-14-24 03:45PM
3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave
(InvestorPlace) +8.00%
Feb-01-24 08:00AM
Immuneering Announces Participation in February Investor Conferences
(GlobeNewswire)
Dec-12-23 08:00AM
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
(GlobeNewswire) -7.11%
Nov-20-23 04:05PM
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
(GlobeNewswire)
Nov-09-23 04:05PM
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
(GlobeNewswire) -11.86%
Oct-12-23 04:05PM
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
(GlobeNewswire) -6.65%
Oct-04-23 04:05PM
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
(GlobeNewswire)
Sep-06-23 08:00AM
Immuneering to Present at the Morgan Stanley Healthcare Conference
(GlobeNewswire)
Aug-03-23 04:05PM
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
(GlobeNewswire)
Aug-02-23 06:09AM
Immuneering Corporation (NASDAQ:IMRX) insiders have significant skin in the game with 28% ownership
(Simply Wall St.)
Jul-05-23 09:55AM
Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet
(Zacks)
Jun-05-23 08:00AM
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
(GlobeNewswire)
May-30-23 08:00AM
Immuneering to Present at the Jefferies Healthcare Conference
(GlobeNewswire) +6.86%
May-04-23 07:25PM
Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates
(Zacks) -8.75%
04:05PM Loading…
04:05PM
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
(GlobeNewswire)
Apr-18-23 09:24AM
Immuneering Announces $30 Million Underwritten Offering
(GlobeNewswire) +9.60%
09:00AM
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
(GlobeNewswire)
04:20AM
Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last?
(Zacks)
Apr-12-23 04:05PM
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
(GlobeNewswire)
Apr-11-23 03:56AM
Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?
(Zacks) +5.78%
Apr-05-23 08:00AM
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
(GlobeNewswire)
Mar-28-23 08:00AM
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
(GlobeNewswire) -7.40%
Mar-27-23 09:55AM
Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade
(Zacks)
Mar-24-23 01:25PM
Why Shares of Immuneering Jumped This Week
(Motley Fool)
Mar-23-23 06:18AM
Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?
(Zacks)
Mar-14-23 04:30PM
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
(GlobeNewswire) +5.62%
Mar-09-23 09:55AM
Does Immuneering Corporation (IMRX) Have the Potential to Rally 210.19% as Wall Street Analysts Expect?
(Zacks) +5.47%
Mar-08-23 07:14AM
Immuneering Corporation (NASDAQ:IMRX) Q4 2022 Earnings Call Transcript
(Insider Monkey) +22.87%
Mar-06-23 05:45PM
Immuneering Corporation (IMRX) Reports Q4 Loss, Misses Revenue Estimates
(Zacks)
04:05PM
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
(GlobeNewswire)
Mar-05-23 06:30PM
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
(GlobeNewswire)
Feb-28-23 08:00AM
Immuneering Announces Participation in March Investor Conferences
(GlobeNewswire)
Feb-27-23 08:00AM
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
(GlobeNewswire)
Feb-05-23 07:18AM
Immuneering Corporation (NASDAQ:IMRX) insiders, who hold 31% of the firm would be disappointed by the recent pullback
(Simply Wall St.)
Jan-31-23 06:50AM
Immuneering To Present at Guggenheim 2023 Oncology Conference
(GlobeNewswire)
Nov-28-22 06:50AM
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations
(GlobeNewswire)
Nov-16-22 06:35AM
Immuneering Third Quarter 2022 Earnings: Revenues Disappoint
(Simply Wall St.)
Nov-10-22 10:15AM
Immuneering Corporation (IMRX) Reports Q3 Loss, Lags Revenue Estimates
(Zacks)
09:00AM
Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights
(GlobeNewswire)
09:00AM
Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC
(GlobeNewswire)
Nov-03-22 06:50AM
Immuneering Announces Participation in November Investor Conferences
(GlobeNewswire) -12.80%
Oct-20-22 06:50AM
Immuneering Appoints Leah R. Neufeld as Chief People Officer
(GlobeNewswire)
Oct-05-22 08:05AM
Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
(GlobeNewswire) -5.80%
Sep-30-22 12:00PM
What Makes Immuneering Corporation (IMRX) a New Buy Stock
(Zacks) +9.15%
06:50AM
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
(GlobeNewswire)
Sep-12-22 09:55AM
Wall Street Analysts See a 148% Upside in Immuneering Corporation (IMRX): Can the Stock Really Move This High?
(Zacks) +10.82%
Sep-05-22 10:21AM
Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104
(Zacks)
Sep-02-22 08:09AM
Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
(GlobeNewswire) +7.05%
Aug-25-22 09:55AM
Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 224%: Here's is How to Trade
(Zacks) -7.35%
06:50AM
Immuneering Announces Participation in September Investor Conferences
(GlobeNewswire)
Aug-10-22 05:55PM
Immuneering Corporation (IMRX) Reports Q2 Loss, Misses Revenue Estimates
(Zacks)
04:05PM
Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights
(GlobeNewswire)
Aug-08-22 12:24PM
Immuneering (NASDAQ:IMRX) shareholders have endured a 77% loss from investing in the stock a year ago
(Simply Wall St.) +11.25%
Jul-22-22 10:01AM
Lumos (LUMO) Soars 9.4%: Is Further Upside Left in the Stock?
(Zacks)
Jul-11-22 07:57AM
What Type Of Shareholders Own The Most Number of Immuneering Corporation (NASDAQ:IMRX) Shares?
(Simply Wall St.)
Jul-08-22 11:40AM
Why This Small-Cap Stock Is Gaining More Than 10% Today?
(Benzinga) +28.85%
Jul-06-22 06:50AM
Immuneering Announces Participation in William Blair Biotech Focus Conference 2022
(GlobeNewswire) +5.80%
May-26-22 05:26PM
Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104
(GlobeNewswire) +11.31%
May-20-22 06:50AM
Immuneering Announces Participation in Upcoming Investor Conferences
(GlobeNewswire)
May-10-22 06:30AM
Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights
(GlobeNewswire) +13.99%
May-09-22 08:54AM
Immuneering Corporation (NASDAQ:IMRX) insiders placed bullish bets worth US$10.0m in the last 12 months
(Simply Wall St.) -12.63%
May-05-22 06:50AM
Immuneering Announces Participation in Citis Biopharma VIRTUAL Co-Panel Day
(GlobeNewswire) -8.36%
Apr-07-22 10:46AM
Oppenheimer Sees Gains of Over 100% in These 3 Beaten-Down Stocks
(TipRanks) +5.09%
Apr-01-22 06:50AM
Immuneering Announces Participation in Piper Sandler AI/ML Investor Conference
(GlobeNewswire) +14.99%
Mar-24-22 06:55AM
Immuneering Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
(GlobeNewswire)
Mar-10-22 08:46AM
Is a Surprise Coming for Immuneering (IMRX) This Earnings Season?
(Zacks)
06:30AM
Immuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
(GlobeNewswire)
Feb-24-22 06:50AM
Immuneering Announces Participation in March Investor Conferences
(GlobeNewswire) +5.46%
Feb-07-22 08:30AM
Should You Buy Immuneering (IMRX) Ahead of Earnings?
(Zacks)
Jan-31-22 12:24PM
What Is The Ownership Structure Like For Immuneering Corporation (NASDAQ:IMRX)?
(Simply Wall St.)
Jan-24-22 06:50AM
Immuneering Announces Participation in Upcoming Investor Conferences
(GlobeNewswire)
Jan-19-22 08:00AM
PepGen Appoints Laurie Keating as Chair of Board of Directors
(GlobeNewswire)
Jan-18-22 06:50AM
Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.
(GlobeNewswire)
Jan-06-22 04:10PM
Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will Host Key External Expert Investor Event
(GlobeNewswire) -8.66%
Jan-03-22 06:50AM
Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance Management
(GlobeNewswire) +5.07%
Dec-16-21 06:50AM
Immuneering Added to the Nasdaq Biotechnology Index
(GlobeNewswire)
Nov-18-21 06:35AM
Immuneering Announces Participation in December Investor Conferences
(GlobeNewswire)
Nov-10-21 06:50AM
Immuneering to Participate in Jefferies 2021 London Healthcare Conference
(GlobeNewswire)
Nov-09-21 06:30AM
Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights
(GlobeNewswire)
Nov-01-21 09:20AM
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth
(Simply Wall St.)
Oct-11-21 06:50AM
Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
(GlobeNewswire) -18.44%
Oct-01-21 06:50AM
Immuneering to Present Key Preclinical Data Across Several Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
(GlobeNewswire) +8.85%
Sep-20-21 04:10PM
Immuneering Announces Inclusion in the Russell 2000® Index
(GlobeNewswire) -11.27%
Sep-09-21 06:30AM
Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates
(GlobeNewswire)
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cormorant Asset Management, LP10% OwnerApr 01 '24Sale2.90400,0001,160,1812,895,273Apr 03 05:37 PM
Feinberg PeterDirectorMar 22 '24Buy2.5525,00063,713111,766Mar 25 09:13 AM
Brakewood Harold EugeneChief Business OfficerMar 22 '24Buy2.573,90010,0153,900Mar 25 09:10 AM
Schall Thomas J.DirectorMar 22 '24Buy2.552,9007,3852,900Mar 25 04:03 PM
Morales MalloryChief Accounting OfficerMar 22 '24Buy2.553931,0008,278Mar 25 09:04 AM
Morales MalloryChief Accounting OfficerMar 21 '24Buy2.721,1073,0097,885Mar 25 09:04 AM
Hall Brett MatthewCHIEF SCIENTIFIC OFFICERMar 20 '24Buy2.867,00020,020345,896Mar 21 09:06 AM
Neufeld Leah RCHIEF PEOPLE OFFICERMar 20 '24Buy2.883,81810,99310,029Mar 21 09:11 AM
Feinberg PeterDirectorMar 19 '24Buy2.5625,00064,00086,766Mar 19 07:04 PM
Zeskind Benjamin J.PRESIDENT AND CEOMar 19 '24Buy2.7720,00055,3262,281,852Mar 19 06:59 PM
BERMAN ANN EDirectorMar 18 '24Buy2.1357,965123,43667,465Mar 19 07:10 PM
Feinberg PeterDirectorMar 18 '24Buy2.3850,000119,05861,766Mar 19 07:04 PM
Cormorant Asset Management, LP10% OwnerMar 15 '24Sale2.14400,000856,4003,295,273Mar 18 05:59 PM
Cormorant Asset Management, LP10% OwnerMar 14 '24Sale3.72509,0911,892,6033,695,273Mar 18 05:59 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.